Charlene Kay

1.4k total citations
31 papers, 954 citations indexed

About

Charlene Kay is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Charlene Kay has authored 31 papers receiving a total of 954 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 14 papers in Cancer Research and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Charlene Kay's work include HER2/EGFR in Cancer Research (16 papers), Breast Cancer Treatment Studies (10 papers) and Advanced Breast Cancer Therapies (6 papers). Charlene Kay is often cited by papers focused on HER2/EGFR in Cancer Research (16 papers), Breast Cancer Treatment Studies (10 papers) and Advanced Breast Cancer Therapies (6 papers). Charlene Kay collaborates with scholars based in United Kingdom, United States and Netherlands. Charlene Kay's co-authors include Arran Turnbull, Simon P. Langdon, Dana Faratian, David J. Harrison, James Meehan, Carlos Martínez-Pérez, Mark Gray, Peter Mullen, Andrew H. Sims and In Hwa Um and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Charlene Kay

31 papers receiving 944 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charlene Kay United Kingdom	16	443	433	366	193	158	31	954
C Liedtke Germany	10	604 1.4×	311 0.7×	543 1.5×	206 1.1×	136 0.9×	47	965
Christina W. Yde Denmark	22	458 1.0×	655 1.5×	323 0.9×	188 1.0×	223 1.4×	59	1.2k
Anna Ehinger Sweden	20	482 1.1×	601 1.4×	566 1.5×	169 0.9×	200 1.3×	43	1.2k
Chris Womack United Kingdom	16	594 1.3×	595 1.4×	205 0.6×	282 1.5×	94 0.6×	34	1.2k
Federica Martorana Italy	14	375 0.8×	326 0.8×	226 0.6×	250 1.3×	85 0.5×	55	869
Kinisha Gala United States	7	532 1.2×	524 1.2×	409 1.1×	412 2.1×	366 2.3×	10	1.1k
Marina Parton United Kingdom	18	955 2.2×	577 1.3×	743 2.0×	298 1.5×	164 1.0×	49	1.6k
Heidi Savage United States	12	731 1.7×	801 1.8×	489 1.3×	389 2.0×	135 0.9×	23	1.4k
Honor J. Hugo Australia	15	433 1.0×	520 1.2×	238 0.7×	126 0.7×	83 0.5×	29	927
Juan Miguel Cejalvo Spain	17	611 1.4×	361 0.8×	343 0.9×	352 1.8×	88 0.6×	71	1.1k

Countries citing papers authored by Charlene Kay

Since Specialization

Citations

This map shows the geographic impact of Charlene Kay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charlene Kay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charlene Kay more than expected).

Fields of papers citing papers by Charlene Kay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charlene Kay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charlene Kay. The network helps show where Charlene Kay may publish in the future.

Co-authorship network of co-authors of Charlene Kay

This figure shows the co-authorship network connecting the top 25 collaborators of Charlene Kay. A scholar is included among the top collaborators of Charlene Kay based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charlene Kay. Charlene Kay is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kay, Charlene, Carlos Martínez-Pérez, J. Michael Dixon, & Arran Turnbull. (2023). The Role of Nodes and Nodal Assessment in Diagnosis, Treatment and Prediction in ER+, Node-Positive Breast Cancer. Journal of Personalized Medicine. 13(10). 1476–1476. 4 indexed citations

Martínez-Pérez, Carlos, Arran Turnbull, Charlene Kay, & J. Michael Dixon. (2023). Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer. Expert Review of Anticancer Therapy. 23(1). 67–86. 5 indexed citations

He, Xiaping, Lorna Renshaw, Carlos Martínez-Pérez, et al.. (2022). Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research. 28(16). 3618–3629. 11 indexed citations

Meehan, James, Mark Gray, Carlos Martínez-Pérez, et al.. (2021). A Novel Approach for the Discovery of Biomarkers of Radiotherapy Response in Breast Cancer. Journal of Personalized Medicine. 11(8). 796–796. 10 indexed citations

Gray, Mark, James Meehan, Arran Turnbull, et al.. (2020). The Importance of the Tumor Microenvironment and Hypoxia in Delivering a Precision Medicine Approach to Veterinary Oncology. Frontiers in Veterinary Science. 7. 598338–598338. 5 indexed citations

Gray, Mark, James Meehan, Carlos Martínez-Pérez, et al.. (2020). Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer. Frontiers in Oncology. 10. 617–617. 78 indexed citations

Meehan, James, Mark Gray, Carlos Martínez-Pérez, et al.. (2020). Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer. Frontiers in Oncology. 10. 628–628. 42 indexed citations

Langdon, Simon P., Charlene Kay, In Hwa Um, et al.. (2019). Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models. Scientific Reports. 9(1). 18742–18742. 22 indexed citations

Koussounadis, Antonis, Simon P. Langdon, In Hwa Um, et al.. (2016). Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer. 16(1). 205–205. 4 indexed citations

10.

Arthur, Laura, Arran Turnbull, Alexey A. Larionov, et al.. (2014). Molecular Changes in Lobular Breast Cancers in Response to Endocrine Therapy. Cancer Research. 74(19). 5371–5376. 25 indexed citations

11.

Argenta, Peter A., Charlene Kay, David J. Harrison, et al.. (2013). Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer. Gynecologic Oncology. 131(2). 368–373. 19 indexed citations

12.

Sims, Andrew H., Annelien J.M. Zweemer, Yoko Nagumo, et al.. (2012). Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. British Journal of Cancer. 106(11). 1779–1789. 38 indexed citations

13.

Kay, Charlene, et al.. (2012). Best Practices For Risk-Based Forecasts Of Land Volatility For Corridor Management And Sustainable Communities. 4 indexed citations

14.

Faratian, Dana, Andrew H. Sims, Peter Mullen, et al.. (2011). Sprouty 2 Is an Independent Prognostic Factor in Breast Cancer and May Be Useful in Stratifying Patients for Trastuzumab Therapy. PLoS ONE. 6(8). e23772–e23772. 41 indexed citations

15.

Faratian, Dana, Annelien J.M. Zweemer, Yoko Nagumo, et al.. (2011). Trastuzumab and Pertuzumab Produce Changes in Morphology and Estrogen Receptor Signaling in Ovarian Cancer Xenografts Revealing New Treatment Strategies. Clinical Cancer Research. 17(13). 4451–4461. 44 indexed citations

16.

Bartlett, John M.S., Cassandra Brookes, Tammy Robson, et al.. (2011). Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial. Journal of Clinical Oncology. 29(12). 1531–1538. 142 indexed citations

17.

Nes, Johanna G. H. van, Esther M. de Kruijf, Dana Faratian, et al.. (2010). COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Research and Treatment. 125(3). 671–685. 47 indexed citations

18.

Faratian, Dana, Alexey Goltsov, Anatoly Sorokin, et al.. (2009). Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab. Cancer Research. 69(16). 6713–6720. 126 indexed citations

19.

Faratian, Dana, Charlene Kay, Tammy Robson, et al.. (2009). Automated image analysis for high‐throughput quantitative detection of ER and PR expression levels in large‐scale clinical studies: The TEAM Trial Experience. Histopathology. 55(5). 587–593. 44 indexed citations

20.

Bartlett, JMS, Cassandra Brookes, Lucinda Billingham, et al.. (2009). A prospectively planned pathology study within the TEAM trial confirms that progesterone receptor expression is prognostic but is not predictive for differential response to exemestane versus tamoxifen.. Cancer Research. 69(2_Supplement). 81–81. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact